Arrowhead Receives Patent Allowance for DPC siRNA Delivery System with Peptide Backbone

Arrowhead Receives Patent Allowance for DPC siRNA Delivery System with Peptide Backbone

PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Research Corporation (NAS: ARWR) , a targeted therapeutics company, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Number 13/326,433 entitled, "Peptide-Based In Vivo siRNA Delivery System." The allowed claims specifically protect the use of targeted melittin or melittin-like peptides to facilitate delivery of siRNA conjugates to hepatocytes. This new patent protection covers the composition of the Dynamic Polyconjugate, or DPC, delivery system used in Arrowhead's RNAi-based drug candidate, ARC-520, against chronic hepatitis B virus infection.

"We continue to expand the IP protection for multiple formulations of our DPC siRNA delivery system," said Dr. Chris Anzalone, President and CEO of Arrowhead. "This current allowance provides patent coverage through 2031 for our hepatitis B candidate, ARC-520, and other potential RNAi-based candidates using the same DPCs."

About Arrowhead Research Corporation

Arrowhead Research Corporation is a clinical stage targeted therapeutics company with development programs in oncology, obesity, and chronic hepatitis B virus infection. The company is leveraging its platform technologies to design and develop peptide-drug conjugates (PDCs) that specifically home to cell types of interest while sparing off-target tissues, create targeted drugs based on the gene silencing RNA interference (RNAi) mechanism, and work with partners to create improved versions of traditional small molecule drugs.

For more information please visit, or follow us on Twitter @ArrowRes. To be added to the Company's email list to receive news directly, please send an email to

Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results and the results of the offering described in this news release may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to sell the securities in the offering described in this news release, to finance our operations, the future success of our scientific studies, our ability to successfully develop drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Arrowhead Research Corporation's most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

Arrowhead Research Corporation
Vince Anzalone, CFA
The Trout Group
Lauren Glaser, 646-378-2972

KEYWORDS:   United States  North America  California


The article Arrowhead Receives Patent Allowance for DPC siRNA Delivery System with Peptide Backbone originally appeared on

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Can't get enough business news?

Sign up for Finance Report by AOL and get everything from retailer news to the latest IPOs delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.